



CONTROLLED SUBSTANCES BOARD

Contact: Chad Zadrazil (608) 266-2112
Room 121A, 1400 East Washington Avenue, Madison
July 13, 2016

The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.

AGENDA

9:30 A.M.

OPEN SESSION - CALL TO ORDER – ROLL CALL

- A. Adoption of Agenda**
- B. Approval of Minutes**
 - 1) **March 15, 2016**
 - 2) **April 20, 2016**
 - 3) **June 9, 2016**
- C. Administrative Matters**
 - 1) Staff Updates
 - 2) Board Members
 - a. Yvonne Bellay – Dept. of Agriculture, Trade, and Consumer Protection Designee
 - b. Alan Bloom – Pharmacologist
 - c. Doug Englebert – Dept. of Health Services Designee
 - d. Franklin LaDien – Pharmacy Examining Board Designee
 - e. Gunnar Larson – Psychiatrist
 - f. Jeffrey Miller – Board of Nursing Designee
 - g. Jason Smith – Attorney General Designee
 - h. Wendy Pietz – Dentistry Examining Board Designee
 - i. Timothy Westlake – Medical Examining Board Designee
 - 3) Liaison Appointments
 - a. Prescription Drug Monitoring Program (PDMP) Liaison
- D. Letter from GW Pharmaceuticals – Discussion and Consideration**
- E. Waupaca County District Attorney’s Request Regarding Furanyl – Discussion and Consideration**
- F. Update on the Wisconsin State Coalition for Prescription Drug Abuse Reduction – Discussion and Consideration**

- G. **Controlled Substance Prescribing Guidelines (2015 Act 269) – Discussion and Consideration**
- H. **DEA Registration Requirement Guidance Request – Discussion and Consideration**
- I. **Prescription Drug Monitoring Program Operations – Discussion and Consideration**
 - 1) Operations Statistics
 - 2) Pharmacy Compliance/Renewal
 - 3) Act 268 Update
- J. **PMPi Release – Discussion and Consideration**
- K. **ePDMP Development Update – Discussion and Consideration**
 - 1) ASAP Format Identification
 - 2) Promotion
 - 3) Survey of Users
 - 4) Demonstration
- L. **Annual and Quarterly Reports – Discussion and Consideration**
 - 1) Annual Board Report: Wis. Stat. 961.36
 - 2) Quarterly PDMP Report: Wis. Stat. 961.385 (5) and (6)
- M. **Report Access – Discussion and Consideration**
 - 1) Wisconsin Crime Lab Reports
 - 2) DEA Reports of Theft, Loss, and Diversion
- N. **Legislation and Rule Matters – Discussion and Consideration**
 - 1) Adopt Clearinghouse Rule 15-068 Relating to the Exclusion of Naloxegol from Scheduling
 - 2) Adopt Clearinghouse Rule 15-083 Relating to Special Use Authorization Measurements
 - 3) Scope for CSB 2.40 Relating to Exclusion of [¹²³I]ioflupane
 - 4) Affirmative Action Order Relating to Butyryl Fentanyl and Beta-Hydroxythiofentanyl
 - 5) Proposals for Amending CSB 4 Relating to Prescription Drug Monitoring Program (Acts 266, 267 and 268)
 - 6) Update on Legislation and Possible or Pending Rule-Making Projects
- O. **Speaking Engagement(s), Travel, or Public Relations Request(s) – Discussion and Consideration**
- P. Informational Items
- Q. Discussion and Consideration of Items Received After Preparation of the Agenda:
 - 1) Introductions, Announcements, and Recognition
 - 2) Presentations of Petition(s) for Summary Suspension
 - 3) Presentation of Proposed Stipulation(s), Final Decision(s) and Order(s)
 - 4) Presentation of Final Decision and Order(s)
 - 5) Informational Item(s)
 - 6) DLSC Matters
 - 7) Status of Statute and Administrative Rule Matters

- 8) Education and Examination Matters
- 9) Credentialing Matters
- 10) Practice Questions
- 11) Legislation / Administrative Rule Matters
- 12) Liaison Report(s)
- 13) Speaking Engagement(s), Travel, or Public Relations Request(s)
- 14) Consulting with Legal Counsel

R. Public Comments

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider closing disciplinary investigations with administrative warnings (ss. 19.85 (1)(b), 440.205 and 961.385(2)(c) Stats.); to consider individual histories or disciplinary data (s. 19.85 (1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

S. **Deliberation on Issuance of Order Suspending Access to the Prescription Drug Monitoring Program**

- 1) 16 CSB 002
- 2) 16 CSB 003

RECONVENE INTO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

T. Voting on Items Considered or Deliberated on in Closed Session, If Voting is Appropriate

ADJOURNMENT

The next scheduled meeting is September 20, 2016.

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held at 1400 East Washington Avenue, Madison, Wisconsin, unless otherwise noted. In order to confirm a meeting or to request a complete copy of the board's agenda, please call the listed contact person. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of disciplinary hearings may be changed by the examiner for the convenience of the parties. Interpreters for the hearing impaired provided upon request by contacting the Affirmative Action Officer, 608-266-2112.